CAR-T Immunotherapy Targeting CD19- ALL
- Conditions
- B-cell Leukemia
- Interventions
- Biological: 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 100
- Registration Number
- NCT04016129
- Locations
- π¨π³
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
π¨π³Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
π¨π³Zhongxi Children Hospital, Shijiazhuang, Hebei, China
Multiple CAR-T Cell Therapy Targeting AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biological: CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
- First Posted Date
- 2019-07-08
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 10
- Registration Number
- NCT04010877
- Locations
- π¨π³
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
Lentiviral FIX Gene Therapy
- Conditions
- Hemophilia B
- Interventions
- Biological: YUVA-GT-F901
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 10
- Registration Number
- NCT03961243
Immune Modulatory DC Vaccine Against Brain Tumor
- Conditions
- Diffuse Intrinsic Pontine Glioma or Glioblastoma
- Interventions
- Biological: Immunomodulatory DC vaccine to target DIPG and GBM
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 10
- Registration Number
- NCT03914768
- Locations
- π¨π³
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
π¨π³Department of Neurosurgery, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China
π¨π³Shenzhen Children's Hospital, Shenzhen, Guangdong, China
IT and IV Lentiviral Gene Therapy for X-ALD
- Conditions
- X-linked Adrenoleukodystrophy
- Interventions
- Genetic: Intracerebral LV gene therapy
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 30
- Registration Number
- NCT03727555
- Locations
- π¨π³
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
Lentiviral Gene Therapy for MLD
- Conditions
- Metachromatic Leukodystrophy (MLD)
- Interventions
- Biological: Lentivirus-mediated delivery of ARSA to the CNS.
- First Posted Date
- 2018-10-31
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 10
- Registration Number
- NCT03725670
- Locations
- π¨π³
Lung-Ji Chang, Shenzhen, Guangdong, China
Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)
- Conditions
- Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)
- Interventions
- Genetic: Direct intravenous injection of ivlv-ADA lentiviral vector
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 10
- Registration Number
- NCT03645460
- Locations
- π¨π³
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
π¨π³Guilin Hospital of Chinese Traditional and Western Medicine, Guilin, Guangxi, China
Lentiviral Gene Therapy for CGD
- Conditions
- Chronic Granulomatous Disease
- Interventions
- Genetic: Infusion of lentiviral TYF-CGD-modified autologous stem cells
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 10
- Registration Number
- NCT03645486
- Locations
- π¨π³
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
Immunotherapy Treating GI Cancer
- Conditions
- Cancer
- Interventions
- Biological: engineered immune cells
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 100
- Registration Number
- NCT03614650
- Locations
- π¨π³
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells
- Conditions
- Cancer
- Interventions
- Biological: Engineered Immune Cells
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 100
- Registration Number
- NCT03535246
- Locations
- π¨π³
Shenzhen Geno-immune Medical Institute, ShenZhen, Guangdong, China
π¨π³QiFu Hospital of Guangzhou University of Chinese Medicine, GuangZhou, Guangdong, China
π¨π³Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, KunMing, Yunnan, China